Stock Scorecard



Stock Summary for Dyne Therapeutics Inc (DYN) - $12.38 as of 8/18/2025 10:18:55 AM EST

Total Score

10 out of 30

Safety Score

40 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for DYN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for DYN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for DYN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for DYN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for DYN (40 out of 100)

Stock Price Rating (Max of 10) 5
Historical Stock Price Rating (Max of 10) 5
Stock Price Trend (Max of 10) 7
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for DYN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN - Dyne Therapeutics ( NASDAQ:DYN ) 8/9/2025 4:38:00 PM
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy ( DMD ) 8/4/2025 11:30:00 AM
Does Dyne Therapeutics ( DYN ) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? 7/31/2025 1:55:00 PM
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss - Dyne Therapeutics ( NASDAQ:DYN ) 7/29/2025 4:51:00 PM
Dyne Reports Wider Loss in Fiscal Q2 7/29/2025 1:33:00 AM
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights 7/28/2025 8:10:00 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN - Dyne Therapeutics ( NASDAQ:DYN ) 7/28/2025 3:46:00 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYN - Dyne Therapeutics ( NASDAQ:DYN ) 7/6/2025 2:00:00 PM
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - AeroVironment ( NASDAQ:AVAV ) , Dyne Therapeutics ( NASDAQ:DYN ) 7/1/2025 1:00:00 PM
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Argo Blockchain ( NASDAQ:ARBK ) , Applied DNA Sciences ( NASDAQ:APDN ) 7/1/2025 9:23:00 AM

Financial Details for DYN

Company Overview

Ticker DYN
Company Name Dyne Therapeutics Inc
Country USA
Description Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The company is headquartered in Waltham, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2025
Next Earnings Date 10/30/2025

Stock Price History

Last Day Price 12.38
Price 4 Years Ago 11.89
Last Day Price Updated 8/18/2025 10:18:55 AM EST
Last Day Volume 1,931,424
Average Daily Volume 3,148,874
52-Week High 47.45
52-Week Low 6.36
Last Price to 52 Week Low 94.65%

Valuation Measures

Trailing PE N/A
Industry PE 43.35
Sector PE 59.06
5-Year Average PE -4.56
Free Cash Flow Ratio 3.63
Industry Free Cash Flow Ratio 15.81
Sector Free Cash Flow Ratio 30.26
Current Ratio Most Recent Quarter 16.83
Total Cash Per Share 3.41
Book Value Per Share Most Recent Quarter 5.00
Price to Book Ratio 3.05
Industry Price to Book Ratio 31.11
Sector Price to Book Ratio 26.93
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 34.46
Sector Price to Sales Ratio Twelve Trailing Months 15.21
Analyst Buy Ratings 9
Analyst Strong Buy Ratings 6

Share Statistics

Total Shares Outstanding 142,264,000
Market Capitalization 1,761,228,320
Institutional Ownership 94.37%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -34.54%
Reported EPS 12 Trailing Months -3.88
Reported EPS Past Year -2.02
Reported EPS Prior Year -3.35
Net Income Twelve Trailing Months -412,885,000
Net Income Past Year -317,418,000
Net Income Prior Year -235,937,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 485,040,000
Total Cash Past Year 435,449,000
Total Cash Prior Year 121,626,000
Net Cash Position Most Recent Quarter 386,227,000
Net Cash Position Past Year 435,449,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 98,813,000
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 0.85
Total Stockholder Equity Past Year 629,838,000
Total Stockholder Equity Prior Year 91,292,000
Total Stockholder Equity Most Recent Quarter 571,445,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -361,929,000
Free Cash Flow Per Share Twelve Trailing Months -2.54
Free Cash Flow Past Year -294,745,000
Free Cash Flow Prior Year -188,887,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.47
MACD Signal 0.18
20-Day Bollinger Lower Band 6.68
20-Day Bollinger Middle Band 10.62
20-Day Bollinger Upper Band 14.56
Beta 1.08
RSI 66.55
50-Day SMA 18.68
150-Day SMA 18.04
200-Day SMA 16.03

System

Modified 8/15/2025 10:27:31 PM EST